Elimination of Hepatic Rodent Plasmodium Parasites by Amino Acid Supplementation

Patricia Meireles, Daniela Brás, Diana Fontinha, Ângelo F. Chora, Karine Serre, António M. Mendes, Miguel Prudêncio

antoniomendes@medicina.ulisboa.pt (A.M.M.)
mprudencio@medicina.ulisboa.pt (M.P.)

HIGHLIGHTS
RKV supplementation leads to the elimination of hepatic P. berghei parasites
An overall activation of the innate immune system mediates parasite elimination
MyD88 is a key player in the elimination of hepatic P. berghei parasites
Elimination of Hepatic Rodent *Plasmodium* Parasites by Amino Acid Supplementation

Patrícia Meireles,1 Daniela Brás,1 Diana Fontinha,1 Ângelo F. Chora,1 Karine Serre,1 António M. Mendes,1,∗ and Miguel Prudêncio1,2,∗

**SUMMARY**

*Plasmodium* parasites, causative agents of malaria, scavenge host nutrients to sustain their intracellular replication. Modulation of the host’s nutritional status can potentially help control infection by limiting the parasite’s access to nutrients, or by boosting the immune system. Here, we show that dietary supplementation of mice employing a combination of arginine (R) with two additional amino acids, lysine (K) and valine (V), termed RKV, significantly decreases *Plasmodium* liver infection. RKV supplementation results in the elimination of parasites at a late stage of their development in the liver. Our data employing genetic knockout mouse models and *in vivo* depletion of specific cell populations suggest that RKV supplementation boosts the host’s overall innate immune response, and that parasite elimination is dependent on MyD88 signaling in immune cells. The immunostimulatory effect of RKV supplementation opens a potential role for dietary supplementation as an adjuvant for prophylaxis or immunization strategies against *Plasmodium* infection.

**INTRODUCTION**

Malaria is an infectious disease that remains a major cause of morbidity and mortality worldwide, for which new cost-effective interventions are urgently needed (WHO, 2019). *Plasmodium* parasites, the causative agents of malaria, are transmitted by female *Anopheles* mosquitoes as sporozoites, which are deposited under the mammalian host’s skin and home to the liver through the circulatory system. After traversing several cells, sporozoites productively invade hepatocytes, inside which they develop into exoerythrocytic forms containing thousands of merozoites. The end of the liver stage of *Plasmodium* infection is marked by the release of these newly formed parasites into the bloodstream, where they invade red blood cells, and initiate the symptomatic, erythrocytic stage of the disease (Prudencio et al., 2006).

Numerous studies suggest that poor nutritional status or nutrient deficiencies increase a population’s vulnerability to infections (Schaible and Kaufmann, 2007; Jones and Berkley, 2014). That is also the case for malaria, for which it is well established that host deficiencies in several micronutrients (e.g., vitamin A and zinc) can exacerbate malaria, and that modulating parasite access to other nutrients, such as glucose, vitamin B5, and choline, can have a significant impact on parasite growth and, consequently, on disease (Kirk and Saliba, 2007; Mancio-Silva et al., 2017; Counihan et al., 2017; Shankar, 2000; Caulfield et al., 2004). Dietary supplementations employing various nutrients, such as Coenzyme Q10, Vitamin C, Vitamin D, iron, Arg, tetrahydrobiopterin (BH4), or folate, among others, have been shown to directly impact *Plasmodium* erythrocytic stages (Nyarki et al., 2019; Qin et al., 2019; Wu et al., 2018; Castberg et al., 2018; Goheen et al., 2017; Awasthi et al., 2017; Aikaitis and Ackerman, 2016; Meadows et al., 2015). Interestingly, cysteamine has been shown to potentiate the activity of anti-malarial drugs, like artemisinins (Moradin et al., 2016), opening a potential new pathway to using nutrient supplementation to improve malaria treatment. Despite numerous studies to understand how different nutrients may affect *Plasmodium* infection, their usefulness as modulators of disease remains largely unexplored.

Conversely, little is known about the effects of dietary supplementation on the liver stage of *Plasmodium* infection. Dietary supplementation of n-3 fatty acids in the form of fish oil has been shown to inhibit *P. berghei* hepatic development (Vreden et al., 1995). Also, the administration of a high-fat diet to mice highly impaired *Plasmodium* liver infection leading to parasite elimination, an effect associated with increased expression of oxidative stress-related genes (Zuzarte-Luis et al., 2017). Interestingly, iron...
supplementation has yielded contradictory results in what concerns its impact on *Plasmodium* liver infection. While one study has suggested that it promotes hepatic parasite development (Goma et al., 1996), another, more recent, study reported a hepcidin-dependent decrease in hepatic parasite numbers following iron supplementation (Ferrer et al., 2016). Thus, a more comprehensive understanding on the impact of dietary alterations on the liver stage of *Plasmodium* infection is clearly warranted.

Arg (R) is involved in many metabolic pathways, including the synthesis of nitric oxide (NO), which plays an important role in the killing of invading pathogens, and the synthesis of polyamines via the arginase pathway, which, in turn, can support pathogen growth (Wanasen and Soong, 2008; Das et al., 2010). The competition between these two pathways has been shown to dictate the outcome of infections by *Trypanosoma* spp., *Leishmania* spp., *Toxoplasma gondii*, *Shistosoma mansoni*, *Candida albicans*, *Helicobacter pylori*, and *Plasmodium* spp. (reviewed in (Das et al., 2010; Phillips, 2018)). Arg is the only amino acid-based dietary supplementation that has been evaluated in the context of malaria. Its administration was reported to increase the circulating levels of Arg in *P. berghei* and *P. yoelii*-infected mice, leading to enhanced NO production (Martins et al., 2012; Zhu et al., 2012). This, in turn, was shown to significantly impact the pathology associated with the blood stage of *Plasmodium* parasites, reversing cerebrovascular constriction in *P. berghei*-infected mice displaying signs of experimental cerebral malaria (Ong et al., 2018). Yet, while some studies employing *P. yoelii*-infected BALB/c and *P. berghei*-infected C57BL/6 mice report a significant decrease in parasitemia and an improvement in the survival of the animals following Arg supplementation (Zhu et al., 2012; Ong et al., 2018), these effects were not observed in another study employing the latter model (Martins et al., 2012). Therefore, although Arg supplementation has been shown to be beneficial for some aspects of the malaria pathology, the role for this amino acid in the context of the disease remains to be clearly defined.

Our previous studies have shown that Arg uptake plays an essential role in the *Plasmodium* parasite’s intra-hepatic development and maturation (Meireles et al., 2017). In the liver, Arg is taken up by the infected hepatocytes through the host cell’s SLC7A2-encoded transporters and is metabolized primarily by the parasite’s own arginase pathway to secure the biosynthesis of polyamines which are crucial for its development (Meireles et al., 2017). This observation led us to hypothesize that the liver stage of *Plasmodium* infection might be impaired by a dietary supplementation that would significantly alter the parasite’s metabolism of Arg. To investigate this, we aimed at blocking the polyamine synthesis pathway of both the parasite and the host cell by providing the amino acids lysine (Lys, K) and valine (Val, V), which are well-known inhibitors of the arginase enzyme (Hunter and Downs, 1945). The blockage of Arg metabolism for polyamine synthesis is expected to channel the use of this amino acid as a substrate of iNOS, boosting NO production and potentially impairing *Plasmodium* development in the liver.

We, therefore, designed an amino acid supplementation regimen named RKV, which combines Arg, R with Lys, K and Val, V and employed the rodent *P. berghei* parasite in combination with different mouse strains to investigate RKV’s impact on *Plasmodium* liver infection. Our results show that RKV supplementation leads to a significant elimination of hepatic *Plasmodium* parasites, likely through the action of the innate immune system, and in an MyD88-dependent manner.

**RESULTS**

**RKV Dietary Supplementation Impairs *P. berghei* Hepatic Infection**

To assess the possibility of modulating hepatic infection by *Plasmodium* through dietary supplementation, we sought to increase the bioavailability of Arg (R) as a physiological substrate for the synthesis of nitric oxide (NO), which is a key mediator of immune responses (Lee et al., 2017; Roth, 1992; Bogdan, 2001). To achieve this, we supplemented the drinking water of *P. berghei*-infected BALB/c mice with 2.5% (w/v) of Arg and the arginase inhibitors Lys (K) and Val (V), either individually or in combinations of equal concentrations (RV, KV, RK, and RKV). Mice were provided with supplemented water ad libitum for 4 weeks, while non-supplemented sterilized water was provided to control (Ctrl) mice, following which all animals were infected by intravenous (iv) injection of luciferase-expressing rodent *P. berghei* sporozoites. Our quantitative real-time polymerase chain reaction (qRT-PCR) results show that RKV supplementation significantly decreased *P. berghei* liver load 46 hr post-infection (hpi) by 65 ± 31%, while supplementation with either the individual components or with any combination of two of the amino acids that make up the RKV formulation did not have a significant impact on liver infection (Figure 1A). This observation is in complete agreement with our bioluminescence analysis of infected mouse livers, which indicated a 63 ± 37% decrease in the hepatic load of RKV-
supplemented mice relative to untreated controls (Figures S1A and S1B). Of note, we also showed that RKV supplementation impacts liver infection by *P. yoelii*, another rodent malaria parasite, to an extent similar to that observed for *P. berghei* (70 ± 12% decrease; Figure S1C), indicating that this phenotype is not species-specific, at least among rodent malaria parasites. When *P. berghei* infection was allowed to proceed to the blood, no significant differences between RKV-supplemented and control mice were observed in terms of pre-patency time or survival from experimental cerebral malaria (Figures S1D and S1E), as expected from a <90% difference in liver parasite load between the two groups of mice (Siddiqui et al., 2015).

Having established that RKV supplementation can significantly impact *Plasmodium* liver infection, we then sought to determine the minimum period of dietary supplementation required for this effect to be observed, by varying the duration of supplementation prior to infection. Our results show that one week of RKV supplementation is sufficient to observe a significant decrease in hepatic infection by *P. berghei* (42 ± 32%), an effect that is even more pronounced after 4 weeks of dietary supplementation (68 ± 25%), and which appears to plateau thereafter (53 ± 28% reduction in comparison to non-supplemented controls after 6 weeks of supplementation; Figure 1B).

**RKV Dietary Supplementation Leads to the Elimination of Late Liver Stage Parasites**

Having shown that RKV leads to a marked decrease in the liver load of *P. berghei*-infected mice, we asked whether this reduction resulted from a decrease in the number of hepatic parasites and/or an impairment of their intra-hepatic growth. To evaluate both possibilities, liver sections from *P. berghei*-infected Ctrl and RKV-supplemented mice were collected 46 hpi and analyzed by immunofluorescence microscopy. Our results show a marked decrease in the number of parasites per liver area of RKV-supplemented mice relative to controls (Figure 2A), as well as a smaller but statistically significant reduction in parasite size (Figure 2B). The decreased number of parasites suggests that RKV supplementation may lead to either a decrease in hepatocyte invasion by the parasite, or to an elimination of parasites developing in the liver of RKV-supplemented mice. To investigate this, livers from Ctrl and RKV-supplemented mice were collected, and parasite load was assessed by qRT-PCR at different times following injection of *P. berghei* sporozoites. Our results show that the establishment of infection in the liver of RKV-supplemented mice is indistinguishable from that of Ctrl mice, indicating that the parasite’s ability to invade and infect hepatocytes is not affected by
this dietary supplementation. Notably, parasite load in the livers of RKV-supplemented mice is lower than that of Ctrl mice only from \( \text{C24} \) 42 hpi onward, suggesting that dietary supplementation leads to the elimination of liver parasites at a late stage of their hepatic development (Figure 2C).

Impairment of Liver Stage Development Is due to a Direct Effect of Lys (K) Dietary Supplementation on \( P. \) berghei Parasites

In order to investigate the direct impact of amino acid supplementation on hepatic \( P. \) berghei parasites, Huh7 cells, a human hepatoma cell line, were infected with luciferase-expressing \( P. \) berghei parasites in the presence of high concentration of either the individual components or with the various combinations of amino acids that make up the RKV formulation. Our results show that supplementation of the culture medium with both Lys alone and the KV combination lead to a marked decrease in hepatic infection \textit{in vitro}, which is stronger than that observed with RKV (Figure 3A). To further investigate this, we infected mouse primary hepatocytes with GFP-expressing \( P. \) berghei parasites, which enable independently assessing the number of infected cells and the extent of parasite development inside these cells by flow cytometry (Prudencio et al., 2008). Our \textit{ex vivo} data clearly show that supplementation with either Lys alone or the KV combination significantly reduces the number of infected hepatocytes at 46 hpi by 63 ± 18% and 50 ± 14%, respectively (Figure 3B), while also decreasing intra-hepatic parasite development by 67 ± 19% and 65 ± 19% (Figure 3C). Also of note, supplementation with Arg alone had no impact on the number of infected hepatocytes (Figure 3B) but markedly increased parasite development at 46 hpi (Figure 3C).

Collectively, these results indicate that, both \textit{in vitro} and \textit{ex vivo}, Lys exerts an inhibitory effect on \( P. \) berghei hepatic infection, whereas Arg enhances development, through direct effects on the parasite. Conversely, in mice, co-supplementation of Arg with Lys and Val, but not with Lys alone, leads to a striking decrease in hepatic parasite numbers (Figure 1A), indicating that the elimination of liver parasites \textit{in vivo} occurs in a mammalian organism-dependent manner and cannot be explained solely on the basis of its direct effect on the parasite’s metabolism. These observations suggest a potential role for the inflammatory or immune responses on the inhibition of liver infection in the context of RKV supplementation.

RKV Dietary Supplementation Does Not Induce Liver Damage or Metabolic Inflammation

To assess the impact of RKV supplementation on the health status of the mice and investigate a potential metabolic inflammation of the liver, we started by analyzing several \textit{in-life} and biochemical parameters in
RKV-supplemented and Ctrl mice. Our results revealed no significant differences between the two groups of mice in terms of mouse weight and water consumption, or the array of plasma parameters analyzed (Table 1).

Furthermore, histological analyses of liver sections from Ctrl and RKV-supplemented mice revealed no alterations in the liver architecture of the latter (Figure S2A), and similar scores of hepatocellular damage and liver inflammatory cell infiltration for both (Figures S2B and S2C). Finally, we analyzed the potential induction of an oxidative stress response in the livers of Ctrl and RKV-supplemented mice by quantifying 16 oxidative stress-related genes, including heme oxygenase-1 (HO-1, encoded by \textit{Hmox1}), an enzyme that has been shown to be upregulated during hepatic \textit{Plasmodium} infection (Epiphanio et al., 2008). Our qRT-PCR data show that the expression of neither of those genes is altered in RKV-supplemented mice in comparison to Ctrl mice (Figure S2D). Overall, our data suggest that a 4-week regimen of RKV dietary supplementation does not bear significant toxicity to the mice or negatively impact their health status.

The Effect of RKV Dietary Supplementation on Hepatic Infection Is Mediated by the Host Immune System but Not Dependent on NO Production

The rationale for formulating the RKV dietary supplementation arose from the hypothesis that the addition of Lys and Val to an Arg-based dietary supplementation might inhibit arginase activity, consequently channeling the available Arg toward NO production by immune cells, and ultimately leading to parasite elimination. To directly test this hypothesis, we compared the liver infection loads of Ctrl and RKV-supplemented Nos2\(^{-/-}\) mice, which cannot produce NO via iNOS. Our results show that RKV dietary supplementation leads to a reduction in liver parasite load for Nos2\(^{-/-}\) mice similar to that observed in WT mice (Figure 4A). We further observed that the expression of iNOS in \textit{P. berghei}-infected, RKV-supplemented, WT mice is similar to that of their non-supplemented counterparts (Figure S3A). Overall, these data indicate that parasite elimination upon RKV dietary supplementation does not depend on an increase in iNOS-mediated NO production. Next, we evaluated whether the observed hepatic parasite elimination could be mediated by an immune response elicited or boosted by the RKV dietary supplementation. First, we assessed the impact of RKV-supplementation on Ifnar\(^{-/-}\) mice, which lack the type-I interferon receptor, to evaluate the role of type I-IFN innate immune responses in the observed decrease in hepatic parasite survival. This innate response has been shown to peak at around 42 hpi following injection of \textit{Plasmodium} sporozoites and to control liver infection (Liehl et al., 2014, 2015; Miller et al., 2014). Our data showed that the absence of type-I IFN signaling does not abolish the decrease in liver parasite load consistently.
observed in RKV-supplemented mice (Figure 4B). Moreover, similar expression levels for several Interferon-stimulated genes (ISGs), namely Ifit1, Ifi44, Usp18, Ifit3 and Irf7, were observed in the livers of Ctrl and RKV-supplemented mice at various time points after infection (Figure S3B). Hence, even though type-II IFN-mediated immune response is active in RKV-supplemented mice, it does not appear to be responsible for the parasite elimination observed. Second, mice that were previously subjected to lethal irradiation, and therefore completely ablated of their immune system (Greenberger and Epperly, 2009; Paix et al., 2018), were supplemented with RKV, in parallel with non-irradiated and non-supplemented Ctrl mice. Our results show that irradiation of RKV-supplemented mice before infection completely abolishes the reduction in liver parasite load observed in supplemented, non-irradiated mice, clearly suggesting an implication of the immune system in parasite elimination upon RKV supplementation (Figure 4C).

**MyD88 Signaling Is Essential for RKV Dietary Supplementation-Mediated Elimination of Hepatic Parasites**

To dissect the components of the immune system directly involved in the mechanism of parasite elimination triggered by RKV dietary supplementation, we used a combination of genetic KO mice and specific antibodies to assess the impact of different immune cell populations in the observed phenotype.

As most of the cells that compose the innate immune compartment are of the myeloid lineage, we started by employing MyD88−/− mice, a mouse strain that lacks a crucial adaptor molecule involved in signal transduction after recognition of pathogens by innate receptors, such as Toll-like receptors (TLRs), which are essential for the function of myeloid cells (Warner and Nunez, 2013; Arnold-Schrauf et al., 2015; Akira and Takeda, 2004). Our results show that, in the absence of MyD88, the reduction in liver parasite load that is typically observed in RKV-supplemented mice is completely abolished, suggesting that MyD88 signaling is essential for parasite elimination (Figure 5A). To ascertain whether the MyD88 signaling process responsible for this effect occurred in hepatocytes or in myeloid cells, we performed a similar experiment employing Alb-Cre.MyD88fl/fl and LysM-Cre.MyD88fl/fl mice, two mouse strains that lack MyD88 specifically in hepatocytes and in myeloid cells, respectively. Our results showed an impairment of *P. berghei* hepatic infection in either Alb-Cre.MyD88fl/fl or LysM-Cre.MyD88fl/fl mice similar to that observed in their WT counterparts (MyD88fl/fl mice; Figure S4A). Although these results strongly indicate that hepatocytes do not play

### Table 1. Mouse Weight, Average Water Intake, and Plasma Biochemistry of Ctrl and RKV-Supplemented Mice

| Parameter                      | Ctrl      | RKV      | p value  |
|--------------------------------|-----------|----------|----------|
| **Mouse weight (g)**           | 22.48 ± 1.97 | 23.45 ± 0.71 | 0.3527 (ns) |
| **Daily water intake (mL)**    | 4.36 ± 0.33  | 4.41 ± 0.56  | 0.9767 (ns) |
| **Serum parameters**           |           |          |          |
| ALT (U per L)                  | 20.33 ± 2.31 | 14.67 ± 2.52  | 0.077 (ns) |
| ALP (U per L)                  | 92.60 ± 20.66 | 100.73 ± 29.10 | 0.070 (ns) |
| AST (U per L)                  | 100.00 ± 5.00 | 111.33 ± 10.79 | 0.400 (ns) |
| GGT (U per L)                  | 1.33 ± 0.58   | 1.33 ± 0.58   | 0.792 (ns) |
| Total protein (g per dl)       | 3.83 ± 0.21   | 3.93 ± 0.38   | 0.700 (ns) |
| Total bilirubin (mg per dl)    | 0.01 ± 0.01   | 0.04 ± 0.02   | 0.110 (ns) |
| BUN (mg per dl)                | 43.03 ± 10.66 | 44.95 ± 0.92  | 1.000 (ns) |
| Creatinine (mg per dl)         | 0.22 ± 0.03   | 0.23 ± 0.05   | 1.000 (ns) |

Data are represented as mean ± SD. p values were determined using the non-parametric two-tailed Mann-Whitney test. See also Figure S2.

ns, not significant; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; BUN, blood urea nitrogen.

*Mouse weight on the day of infection. N = 2 independent experiments.

Average daily water intake per mouse on the fourth week of supplementation. N > 3 independent experiments.

Concentration in the plasma at the time of liver collection (45-46 hpi). N = 3 independent experiments.
a crucial role in the observed phenotype, a similar conclusion cannot be taken with certitude in the case of the myeloid compartment, as there is evidence that this KO strategy may not be fully efficacious for the various myeloid cell populations (Clausen et al., 1999; Abram et al., 2014). Therefore, we decided to confirm these results by employing alternative methods to deplete the different myeloid cell populations, including phagocytic cells, such as Kupffer cells and macrophages, as well as neutrophils and monocytes.

We started by administering liposome-encapsulated clodronate to RKV-supplemented mice in order to completely eliminate Kupffer cells and strongly reduce the presence of monocytes/macrophages in the liver, as shown by the reduction of expression of the Clec4f, CD68 and F4/80 markers in the liver (Figure S4B). Importantly, our results showed that depleting phagocytes does not abolish the reduction in liver parasite load typically observed upon RKV supplementation, suggesting that these cells are not involved in the process of RKV-mediated hepatic parasite elimination (Figure 5B). Next, we assessed the involvement of both neutrophils and monocytes, independently or in combination, on the mechanism of parasite elimination by RKV supplementation. Our results show that neither of these innate immune cells play a critical role in the observed reduction of parasite survival. RKV supplementation of Genista mice, a mouse model that lacks mature neutrophils (Ordonez-Rueda et al., 2012), as well as of mice injected with the monocyte-depleting anti-CCR2 antibody, displayed a reduction in liver parasite load similar to that observed in RKV-supplemented WT mice, thus excluding neutrophils and monocytes from playing an essential role in the mechanism of RKV-mediated parasite elimination (Figures 5B and S4C). Furthermore, administration of the anti-Gr-1 antibody confirmed and expanded these results showing that even the simultaneous depletion of both neutrophils and monocytes does not abolish the reduction in liver parasite load observed upon RKV supplementation (Figures 5B and S4D). Collectively, these results suggest a crucial role for MyD88 signaling in the process of RKV-dependent parasite elimination and exclude hepatocytes and the main myeloid cell populations as key players in this mechanism.

**RKV-Dependent Hepatic Parasite Elimination Results from the Coordinated Action of Various Host Innate Immune Cell Populations**

Having excluded the involvement of the most abundant myeloid cell populations from the mechanism of parasite elimination by RKV supplementation, we proceeded to investigate the possible involvement of lymphoid cells in this process. To this end, we employed Rag2−/− mice, which lack B, T, natural killer (NK) T cells and γδ T cells (Shinkai et al., 1992; Cording et al., 2018), and Rag2−/−γ−/− mice, which, in addition to these cells, also lack NK cells and innate lymphoid cells (ILCs) (Mazurier et al., 1999; Cording et al., 2018). Our results showed

Figure 4. RKV-Dependent Parasite Elimination Is Immune-Mediated but Does Not Rely on NO Production

Ctrl and RKV-supplemented mice were allowed to drink *ad libitum* for 4 weeks, after which they were infected with *P. berghei* sporozoites and parasite liver load was assessed by qRT-PCR 46 hpi. (A) Nos2−/− mice were employed to assess whether NO production via iNOS is involved in RKV-dependent hepatic parasite elimination. (B) Ifnar−/− mice were employed to determine whether the RKV-dependent parasite elimination mechanism is dependent on a boost of the type-I IFN response. Pool of >3 independent experiments. (C) WT mice were irradiated with 900 rad one day prior to infection with *P. berghei* sporozoites. Pool of 2 independent experiments. Error bars representing SEM. Significant differences established by two-tailed Mann-Whitney test (A) or Unpaired t test (B and C) with *p < 0.05 and ***p < 0.001. Phenotype reversion shown in yellow. See also Figure S3.
that while RKV-supplemented Rag2−/− mice display a reduction in hepatic parasite load similar to that observed in RKV-supplemented WT mice, RKV-supplemented Rag2−/−γ−/− mice display a liver parasite load similar to that of their non-supplemented Ctrl counterparts (Figure 5C). These results suggest a possible role of NK cells and/or ILCs in the mechanism of RKV-mediated impairment of liver infection, excluding the main adaptive lymphocyte populations from an involvement in parasite elimination by RKV supplementation. Thus, we next assessed the specific contribution of NK cells to this phenotype, through the administration of the depleting anti-NK1.1 antibody to RKV-supplemented and Ctrl mice. Our results showed that depleting approximately 90% of the NK cells in the liver (defined as NK1.1+TCRβ+ cells; Figure S4E) does not abolish the reduction in the liver parasite load typically observed upon RKV supplementation, excluding NK cells as the sole player in the RKV-related impairment of hepatic infection (Figure 5D).

Figure 5. MyD88 Signaling Is Essential for the Multidimensional Stimulation of the Host’s Innate Immune System Induced by RKV Supplementation

All Ctrl and RKV-supplemented mice were allowed to drink ad libitum for 4 weeks, after which they were infected with *P. berghei* sporozoites and parasite liver load was assessed by qRT-PCR 46 hpi. (A) MyD88−/− mice were employed to assess the role of innate immunity and myeloid cells in hepatic parasite elimination. (B) Phagocytes were depleted through the administration of liposome-encapsulated clodronate 2 days before sporozoite injection. The role of neutrophils on RKV-dependent parasite elimination was investigated employing Genista mice, which lack mature neutrophils. Monocytes were depleted by the daily injection of anti-CCR2 antibody from day −2 to day 1 post-infection. Finally, anti-Gr1 was administered to WT mice 2 hr after sporozoite injection, in order to deplete both neutrophils and monocytes simultaneously. Anti-CCR2: 1 experiment; All others: pools of 3 independent experiments. (C) WT, Rag2−/− and Rag2−/−γ−/− mice were supplemented with RKV for 4 weeks before infection with *P. berghei* sporozoites. Rag2−/− mice lack all the adaptive lymphoid populations while Rag2−/−γ−/− mice also lack NK cells and ILCs, which are innate immune populations. Pools of >3 independent experiments. (D) NK cells were depleted through the administration of anti-NK1.1 antibody, 1 day before infection with *P. berghei* sporozoites. Pool of 3 independent experiments. (E) Ctrl and RKV-supplemented Rag2−/− mice were injected with anti-Thy1.2 antibody, 1 day before infection with *P. berghei* sporozoites, to deplete ILCs. One experiment. All panels: Error bars represent SEM. Significant differences established by unpaired t test (A, D, and E) or Two-tailed Mann-Whitney test (B and C) with *p < 0.05, **p < 0.01 and ***p < 0.001. Phenotype reversion shown in yellow. See also Figure S4.
Finally, we tested whether the reduction in liver parasite load observed upon RKV dietary supplementation could result from the action of ILCs. To test this hypothesis, we injected the anti-Thy1.2 antibody into Rag2−/− mice, leading to the depletion of around 90% of the ILCs in the liver (defined as CD45+ Lineage “CD127+” cells; Figure S4F). However, the liver parasite load in supplemented, ILC-depleted mice did not revert to levels similar to those observed in the corresponding Ctrl mice (Figure 5E), suggesting that ILCs are not, by themselves, responsible for the mechanism of RKV-dependent hepatic parasite elimination.

Collectively, these results suggest that *P. berghei* elimination from the livers of RKV-supplemented mice is mediated by the simultaneous action of several components of the innate immune system, rather than depending on a single population of immune cells.

**DISCUSSION**

Nutritional supplementation has long been suggested as a possible strategy to impact the outcome of several pathogenic infections (Read et al., 2019; Jimenez-Sousa et al., 2018; Rautiainen et al., 2016; Steinbrenner et al., 2015; Stephensen, 2001; Gois et al., 2017; Somerville et al., 2016). Recently, dietary alterations have been shown to significantly alter the capacity of *Plasmodium*, the malaria parasite, to replicate in the blood of its mammalian host, altering the clinical outcome of infection (Shankar, 2000, Clinton Health Access Initiative, 2016, Caulfield et al., 2004, (MSF), 2013, Nyanki et al., 2019; Qin et al., 2019; Wu et al., 2018; Castberg et al., 2018; Goheen et al., 2017; Awasthi et al., 2017; Alkaitis and Ackerman, 2016; Meadows et al., 2015; Kirk and Saliba, 2007; Mancio-Silva et al., 2017; Counihan et al., 2017). Less is known about the impact of dietary alterations on the capacity of this parasite to complete the initial stage of its mammalian infection in the liver, and on how targeted modifications of nutritional availability can be employed as infection control tools (Vreden et al., 1995; Zuzarte-Luis et al., 2017; Goma et al., 1996; Ferrer et al., 2016). This study aimed at establishing a dietary supplementation that could be used to modulate the establishment of a hepatic infection by *Plasmodium* parasites. We selected the amino acid Arg and its metabolism as the main targets of our approach, due to its well established impact on the host’s immune response to infection by various microorganisms, including *Plasmodium* (Wijendra et al., 2015; Li et al., 2007; Badurdeen et al., 2015; Wanasa and Soong, 2008; Peluffo et al., 2004; Ralph et al., 2008; Appleton, 2002; Awasthi et al., 2017). We show that a novel dietary supplementation, named RKV, based on the combination of two other amino acids, Lys and Val, known for their capacity to inhibit arginase, leads to the elimination of rodent *Plasmodium* parasites in vivo at a late stage of their hepatic development, resulting in a strong overall reduction in liver parasite load.

Our *in vitro* and *ex vivo* data indicate that hepatic infection is inhibited by Lys and enhanced by Arg, through direct effects exerted by these amino acids on the parasite. This is in agreement with the notion that Lys competes with Arg for cellular uptake (Lerzynski et al., 2006) and that arginase inhibition by Lys decreases the availability of polyamines required for parasite development (Meireles et al., 2017), with a smaller but significant impact on parasite numbers. On the other hand, supplementation with Arg does not alter the number of parasites successfully infecting the liver but enhances their development (*Figure 3C*), likely through an increase in polyamine production, in agreement with (Meireles et al., 2017). However, in an *in vivo* setting, in the presence of a functioning immune system and upon co-supplementation with Lys and Val, but not of Lys alone, Arg contributes to an immune response that leads to the significant elimination of liver stage parasites (*Figure 1A*). Thus, the small but significant decrease in parasite development observed in an *in vivo* setting (*Figure 2B*) can be explained by a combined Lys- and Val-dependent direct effect on the parasite, whereas the marked reduction in parasite numbers is explained by the immunomodulatory effect of Arg in the context of additional Lys and Val supplementation. Interestingly, while the addition of Val *in vitro* and *ex vivo* seems to be dispensable, our results show that addition of this amino acid *in vivo* is essential to maximize the impact of supplementation on liver parasite load, as the effect of RKV supplementation is not as strong as that observed with RKV.

To the best of our knowledge, this is the first report showing that a specific amino acid combination is able to stimulate the elimination of *Plasmodium* hepatic parasites. Our results suggest that this elimination is dependent on a coordinated response by the innate branch of the immune system. The reduction in liver parasite load typically observed in RKV-supplemented mice is completely abolished, not only in mice subjected to lethal irradiation but also specifically in mice lacking the adaptor molecule MyD88, which are unable to activate the inflammatory signaling pathways downstream of TLRs and IL-1 receptor families.
(Warner and Nunez, 2013; Akira and Takeda, 2004). Furthermore, phenotypic reversion can also be observed in Rag2−/−γ−/− mice, which lack NKs and ILCs in addition to all the B-cell receptor- and T cell receptor (TCR)-containing cell populations, but not on Rag2−/− mice, which only lack the latter cellular subsets. These results exclude the involvement of B and T cells, the main components of the adaptive immune system, as well as NK T cells and γδ T cells, which have innate-like features but are also depend on a functional TCR, from the mechanism of RKV-dependent parasite elimination. Even though our work with KO mouse models points to a critical role for the innate compartment of the immune system in the RKV-dependent impairment of Plasmodium hepatic infection, parasite elimination cannot be attributed to either a single myeloid cell population or a single ILC population. Our results using Lys-M-Cre.MyD88f/f mice and Genius mice, as well as various depleting antibodies, show that the absence of different phagocyte populations, neutrophils and monocytes, did not revert the phenotype associated with the RKV supplementation, while an identical result was obtained for specific ILC populations, namely NK cells and ILCs. Collectively, our data suggest that RKV supplementation might induce an overall boost of the immune system, ultimately leading to parasite elimination in the liver. Importantly, while supplementation of P. yoelii-infected BALB/c mice with Arg alone is sufficient to decrease blood stage parasitemia (Zhu et al., 2012), our results indicate that single supplementation of P. berghei-infected C57BL/6 mice with either of the amino acids, Arg, Lys or Val does not lead to hepatic parasite elimination, and only their combination in the RKV formulation significantly decreases parasite load. Moreover, in C57BL/6 mice, the activity of iNOS is not required for RKV-mediated suppression of hepatic infection, excluding a direct role of NO in parasite killing as a result of this dietary supplementation. In fact, although the role of Arg as a modulator of the immune system is well established (Kang et al., 2014; Nieves and Langkamp-Henken, 2002; Bronte and Zanovello, 2005; Peranzoni et al., 2007), promoting antigen presentation in dendritic cells, influencing B-cell secretion of immunoglobulins and modulating T cell metabolism, survival, proliferation, and anti-tumor activity (Li et al., 2019; Liu et al., 2019; Geiger et al., 2016; Werner et al., 2016), the specific complex mechanisms behind its activity are not yet fully understood. In the context of Plasmodium infection, treatment with Arg was shown to promote an enhanced Th1 cell response during the early stages of P. yoelii blood stage infection in BALB/c mice, and to facilitate the latter’s humoral immune response, leading to a significant decrease in parasitemia (Wang et al., 2018). However, the role of NO in this inhibition of blood stage parasite development remains poorly understood, with several studies pointing to an immunoregulatory rather than a direct anti-parasitic role of NO in Plasmodium infection, in agreement with our observations (Favre et al., 1999; Legorreta-Herrera et al., 2011; Garnica et al., 2003; Jacobs et al., 1999).

Even though the influence of nutrition on malaria is scarcely understood, targeted nutritional supplementation (e.g. iron and folic acid) is known to modulate malaria immunity and pathology (Shankar, 2000, Clinton Health Access Initiative, 2016, Caulfield et al., 2004, (MSF), 2013). Our work raises the possibility of using Arg-based dietary supplementation as a strategy to stimulate the immune system against hepatic forms of Plasmodium. The impact of RKV supplementation on the parasite’s hepatic infection supports its evaluation as a potential low-cost, safe, and effective formulation to be employed as prophylactic or adjunctive therapy for malaria (Shankar, 2000; Clinton Health Access Initiative, 2016).

Limitations of the Study
This study addresses the effect of amino acid supplementation on rodent Plasmodium parasites. These results should not be directly extrapolated to human malaria parasites.

To infect animals, infected mosquitoes were dissected and injected intravenously into mice, which does not correspond to the natural route of infection.

Mice were irradiated in order to study the role of the immune system on the RKV-mediated inhibition of hepatic infection. This procedure eliminates hematopoietic stem cells and their progeny (immune cells) but also damages other cells in the body, such as erythrocytes and enterocytes, which might affect normal physiological function of the host.

Depleting-antibody treatments were employed to study the role of specific populations of immune cells. These antibodies might have off-targets effects and may lead to the elimination of other cells (which might have residual expression of the intended target receptor).
Finally, only one concentration of each amino acid was used in our supplementation experiments. Further experiments are needed to ascertain if these concentrations are the most effective in terms of anti-Plasmodium activity, whilst ensuring the absence of toxicity to the host.

Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contacts, Miguel Prudêncio (mprudencio@medicina.ulisboa.pt) and António M. Mendes (antoniomendes@medicina.ulisboa.pt).

Materials Availability
This study did not generate new unique reagents.

Data and Code Availability
All data generated or analyzed during this study will be available from the lead contacts upon request.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101781.

ACKNOWLEDGMENTS
We are very grateful to Matthias Mack (University Hospital Regensburg, Germany) for kindly providing the anti-CCR2 antibody, to Marie Malissen (Center d’Immunologie Marseille-Luminy, France) for kindly providing the Genista mice, to Marc Veldhoen (iMM) for the anti-Thy1.2 antibody and for discussions on ILCs, to Tânia Carvalho (iMM) for the Histopathology Analyses of mouse organs, to Carolina Andrade (iMM) for her contribution to mouse supplementation and sample processing, to Filipa Teixeira (iMM) for producing P. berghei-infected mosquitoes, and to the iMM’s Flow Cytometry, Bioimaging, Histology and Rodent facilities for technical support. This work was supported by Fundação para a Ciência e a Tecnologia, Portugal, through Grant PTDC/SAU-INF/29550/2017 to MP.

AUTHOR CONTRIBUTIONS
P.M., A.M.M. and M.P. conceived the study. P.M., D.B. and D.F. performed the experiments. A.C and K.S. gave intellectual input to the work. P.M., A.M.M. and M.P. wrote the manuscript. M.P. supervised the work. All authors were involved in revising and editing the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: August 25, 2020
Revised: October 16, 2020
Accepted: November 4, 2020
Published: December 18, 2020

REFERENCES
Abram, C.L., Roberge, G.L., Hu, Y., and Lowell, C.A. (2014). Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J. Immunol. Methods 408, 89–100.

Akira, S., and Tsukada, K. (2004). Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511.

Alkaitis, M.S., and Ackerman, H.C. (2016). Tetrahydrobiopterin supplementation improves phenylalanine metabolism in a murine model of severe malaria. ACS Infect. Dis. 2, 827–838.

Appleton, J. (2002). Arginine: clinical potential of a semi-essential amino acid. Altern. Med. Rev. 7, 512–522.

Arnold-Schrauf, C., Berod, L., and Sparwasser, T. (2015). Dendritic cell specific targeting of MyD88 signalling pathways in vivo. Eur. J. Immunol. 45, 32–39.

Awasthi, V., Chauhan, R., Chattopadhyay, D., and Das, J. (2017). Effect of L-arginine on the growth of Plasmodium falciparum and immune modulation of host cells. J. Vector Borne Dis. 54, 139–145.
Badureen, S., Mulongo, M., and Berkley, J.A. (2015). Arginine depletion increases susceptibility to serious infections in preterm newborns. Pediatr. Res. 77, 290–297.

Bogdan, C. (2001). Nitric oxide and the immune response. Nat. Immunol. 2, 907–916.

Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641–654.

Castberg, F.C., Maretty, L., Staalsoe, T., Hempel, C., Clasen-Linde, E., Hvid, L., and Kurthals, J.A.L. (2018). Increased Plasmodium chabaudi malaria mortality in mice with nutritional iron deficiency can be reduced by short-term adjunctive iron supplementation. Malar. J. 17, 34.

Caulfield, L.E., Richard, S.A., and Black, R.E. (2004). Undernutrition as an underlying cause of malaria morbidity and mortality in children less than five years old. Am. J. Trop. Med. Hyg. 71, 55–63.

Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. (1999). Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265–277.

Chilton Clinton Health Access Initiative. I.C. (2016). Impact of Integrating the Delivery of Seasonal Malaria Chemoprevention (Smc) with Nutrition Supplementation in Northern Nigeria on Malaria and Nutrition Outcomes.

Cording, S., Medvedovic, J., Lecuyer, E., Aychek, A., et al. (2008). Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine experimental cerebral malaria. J. Immunol. 180, 1407–1416.

Das, P., Lahiri, A., Lahiri, A., and Chakravortty, D. (2010). Modulation of the arginase pathway in the inflammatory host response. Semin. Radiat. Oncol. 19, 133–139.

Jones, K.D., and Berkley, J.A. (2014). Severe acute malnutrition and infection. Paediatr. Int. Child Health 34 (Suppl 1), S1–S29.

Kirk, K., and Saliba, K.J. (2007). Targeting nutrient uptake mechanisms in Plasmodium. Curr. Drug Targets 8, 53–106.

Liehl, P., Meireles, P., Albuquerque, I.S., Pinkeych, M., Baptista, F., Mota, M.M., Davenport, M.P., and Prudencio, M. (2015). Invasive immunity induced by Plasmodium liver infection inhibits malaria reinfections. Infect. Immun. 83, 1172–1180.

Liu, S., Tan, J., Hu, Y., Jia, X., Kogut, M.H., Yuan, J., and Zhang, H. (2019). Dietary L-arginine supplementation influences growth performance and B-cell secretion of immunoglobulin in broiler chickens. J. Anim. Physiol. Anim. Nutr. (Berl) 103, 1125–1134.

Mancio-Silva, L., Slavic, K., Grito Ruivo, M.T., Grosso, A.R., Modrzyńska, K.K., Vera, I.M., Sales Dias, J., Gomes, A.R., Macpherson, C.R., Crozet, P., et al. (2017). Nutrient sensing modulates malaria parasite virulence. Nature 547, 213–216.

Martins, Y.C., Zannini, G.M., Frangos, J.A., and Carvalho, L.J. (2012). Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by Plasmodium berghei ANKA. PLoS One 7, e32048.

Mazurier, F., Fontanellas, A., Salesse, S., Taine, L., Landriau, S., Moreau-Gaudry, F., Reiffers, J., Pauilt, B., Di Santo, J.P., and De Verneuil, H. (1999). A novel immunodeficient mouse model—RAG2 x common cytokine receptor gamma chain double mutants—requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J. Interferon Cytokine Res. 19, 533–541.

Meade, D.N., Bahous, R.H., Best, A.F., and Rozen, R. (2015). High fat alters immune response and reduces survival after malarial infection. PLoS One 10, e0143738.

Meireles, P., Mendes, A.M., Areiove, R.I., Mounce, B.C., Vignuzzi, M., Staines, H.M., and Prudencio, M. (2017). Uptake and metabolism of arginine impact Plasmodium development in the liver. Sci. Rep. 7, 1027.

Miller, J.L., Sack, B.K., Baldwin, M., Vaughan, A.M., and Kappe, S.H.I. (2014). Interferon-mediated innate immune responses against malaria parasite liver stages. Cell Rep. 7, 436–447.

Moradin, N., Torre, S., Gauthier, S., Tam, M., Hawari, J., Vanderwyk, K., De Spiegeleer, B., Fortin, A., Stevenson, M.M., and Goss, P. (2016). Cysteine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria. Malar. J. 15, 260.

MSF. 2013. Niger 2013 - Tackling the Deadly Combination of Malaria and Malnutrition.
Arginine and immunity: a unique perspective.
Nieves, C., Jr., and Langkamp-Henken, B. (2002). Arginine and immunity: a unique perspective. Biomed. Pharmacother. 56, 471–482.

Nyanki, J.N., Ochola, L.A., Jillani, N.E., Nyamweya, N.O., Armwary, P.E., Yole, D.S., Azonvide, L., and Isaac, A.O. (2019). Oral administration of Coenzyme Q10 protects mice against oxidative stress and neuro-inflammation during experimental cerebral malaria. Parasitol. Int. 71, 106–120.

Ong, P.K., Moreira, A.S., Daniel-Ribero, C.T., Frangos, J.A., and Carvalho, L.J.M. (2018). Reversal of cerebrovascular constriction in experimental cerebral malaria by L-arginine. Sci. Rep. 8, 15957.

Ordonez-Rueda, D., Jonsson, F., Mancardi, D.A., Zhao, W., Malzac, A., Liang, Y., Bertosio, E., Grenot, P., Blanquet, V., Sabrautzki, S., et al. (2012). A hypomorphic mutation in the Gfi1 transcriptional repressor results in a novel form of neutropenia. Eur. J. Immunol. 42, 2395–2408.

Paix, A., Antoni, D., Waissi, W., Ledoux, M.P., Bilger, K., Fornecker, L., and Noel, G. (2018). Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: a review. Crit. Rev. Oncol. Hematol. 123, 138–148.

Peluffo, G., Piacenza, L., Irigoin, F., Alvarez, M.N., and Radi, R. (2004). L-arginine metabolism during interaction of Trypanosoma cruzi with host cells. Trends Parasitol. 20, 363–369.

Peranzoni, E., Marigo, I., Dolcetti, L., Ugel, S., Sonda, N., Taschin, E., Mantelli, B., Bronte, V., and Zanovello, P. (2007). Role of arginine metabolism in immunity and immunopathology. Immunobiology 212, 795–812.

Phillips, M.A. (2018). Polyamines in protozoan pathogens. J. Biol. Chem. 293, 18746–18756.

Prudencio, M., Rodrigues, C.D., Ataide, R., and Mota, M.M. (2008). Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Cell Microbiol. 10, 218–224.

Prudencio, M., Rodrigues, A., and Mota, M.M. (2006). The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 4, 849–856.

Qin, X., Liu, J., Du, Y., Li, Y., Zheng, L., Chen, G., and Cao, Y. (2019). Different doses of vitamin C supplementation enhances the Th1 immune response to early Plasmodium yoelii 17XL infection in BALB/c mice. Int. Immunopharmacol. 70, 387–395.

Ralph, A.P., Kelly, P.M., and Anstey, N.M. (2008). L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol. 16, 336–344.

Rautianen, S., Manson, J.E., Lichtenstein, A.H., and Sesso, H.D. (2016). Dietary supplements and disease prevention - a global overview. Nat. Rev. Endocrinol. 12, 407–420.

Read, S.A., Obeid, S., Ahlenstiel, C., and Ahlenstiel, G. (2019). The role of zinc in antiviral immunity. Adv. Nutr. 10, 696–710.

Roth, J.V. (1992). Temporary transmyocardial pacing using epicardial pacing wires and pacing pulmonary artery catheters. J. Cardiothorac. Vasc. Anesth. 6, 663–667.

Schable, U.E., and Kaufmann, S.H. (2007). Malnutrition and infection: complex mechanisms and global impacts. PLoS Med. 4, e115.

Shankar, A.H. (2000). Nutritional modulation of malaria morbidity and mortality. J. Infect. Dis. 182 (Suppl 1), S37–S53.

Shinkai, Y., Rathburn, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., Stall, A.M., et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867.

Siddiqui, A.J., Bhardwaj, J., Goyal, M., Prakash, K., Soni, A., Tiwari, V., and Puri, S.K. (2015). Assessment of real-time method to detect liver parasite burden under different experimental conditions in mice infected with Plasmodium yoelii sporozoites. Microb. Pathog. 89, 35–42.

Somerville, V.S., Braakhuis, A.J., and Hopkins, W.G. (2016). Effect of flavonoids on upper respiratory tract infections and immune function: a systematic review and meta-analysis. Adv. Nutr. 7, 488–497.

Steinbrenner, H., Al-Quraishy, S., Dikhil, M.A., Wunderlich, F., and Sies, H. (2015). Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv. Nutr. 6, 73–82.

Stephensen, C.B. (2001). Vitamin A, infection, and immune function. Annu. Rev. Nutr. 21, 167–192.

Vreden, S.G., Blok, W.L., Sauerwein, R.W., Oettinger, M.C., Verhave, J.P., Meuwissen, J.E., van der Meer, J.W., and van den Broek, M.F. (1995). Inhibition of Plasmodium berghei liver schizont development and reduction of cytokine production capacity in rats by dietary fish oil supplementation. Am. J. Trop. Med. Hyg. 53, 206–210.

Wanasen, N., and Soong, L. (2008). L-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol. Res. 41, 15–25.

Wang, Q., Feng, Y., Sun, X., Pang, W., Fu, W., and Cao, Y. (2018). Prophylactic treatment of L-Arg improves malaria outcomes by regulating host immune responses during Plasmodium yoelii 17XL infection. Exp. Parasitol. 195, 1–7.

Warner, N., and Nunez, G. (2013). MyD88: a critical adaptor protein in innate immunity signal transduction. J. Immunol. 190, 3–4.

Werner, A., Amann, E., Schnitzius, V., Habermeier, A., Luckner-Minden, C., Leuchtner, N., Rupp, J., Closs, E.I., and Munder, M. (2016). Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation. Eur. J. Immunol. 46, 92–103.

WHO 2019. World Malaria Report.

Wijnands, K.A., Castermans, T.M., Hommen, M.P., Meesters, D.M., and Poeze, M. (2015). Arginine and citrulline and the immune response in sepsis. Nutrients 7, 1426–1463.

Wu, B., Du, Y., Feng, Y., Wang, Q., Pang, W., Qi, Z., Wang, J., Yang, D., Liu, Y., and Cao, Y. (2018). Oral administration of vitamin D and importance in prevention of cerebral malaria. Int. Immunopharmacol. 64, 356–363.

Zhu, X., Pan, Y., Li, Y., Cui, L., and Cao, Y. (2012). Supplement of L-Arg improves protective immunity during early-stage Plasmodium yoelii 17XL infection. Parasite Immunol. 34, 412–420.

Zuzzate-Luis, V., Mello-Vieira, J., Marreiros, I.M., Liel, P., Chora, A.F., Carret, C.K., Carvalho, T., and Mota, M.M. (2017). Dietary alterations modulate susceptibility to Plasmodium infection. Nat. Microbiol. 2, 1600–1607.
Supplemental Information

Elimination of Hepatic Rodent *Plasmodium* Parasites by Amino Acid Supplementation

Patrícia Meireles, Daniela Brás, Diana Fontinha, Ângelo F. Chora, Karine Serre, António M. Mendes, and Miguel Prudêncio
Figure S1 (Related to Figure 1)– RKV supplementation significantly impacts liver parasite load but does not affect blood stage infection or mouse survival. The drinking water of C57BL6 WT mice was supplemented with the RKV combination for 4 weeks prior to infection with luciferase-expressing *P. berghei* (A, B, D and E) or with *P. yoelii* (C) sporozoites. (A) Liver parasite load was assessed at 46 hpi by bioluminescence. Pool of 3 independent experiments. (B) Representative image of bioluminescence assessment of liver infection in Ctrl and RKV-supplemented mice. (C) Liver parasite load in *P. yoelii*-infected mice was assessed at 46 hpi by qRT-PCR. One experiment. (D) Blood parasite load in Ctrl and RKV-supplemented mice, assessed by a bioluminescence assay. Representative experiment out of 2 independent experiments. (E) Survival of Ctrl and RKV-supplemented mice after infection. Pool of 2 independent experiments. (A and C) Two-tailed Mann-Whitney, (D) Two-way ANOVA with post-test Bonferroni, (E) Log-Rank Mantel-Cox test. Error bars represent SEM. ** p < 0.01 and *** p < 0.001.
Figure S2 (Related to Table 1)– RKV supplementation does not cause liver toxicity or an increased inflammatory state. (A) Representative microphotographs of liver sections from Ctrl and RKV-supplemented mice stained with HE. Insets show a normal aspect and organization of the liver cells. (B) Hepatocellular damage score of livers from Ctrl and RKV-supplemented mice. (C) Hepatic inflammatory cell infiltration score in livers from Ctrl and RKV-supplemented mice at 39 hpi. (B and C) One experiment with 5 mice per group. (D) Expression of several oxidative stress-related genes in whole livers of Ctrl and RKV-supplemented mice at 46 hpi. Pool of 3 independent experiments. Two-tailed Mann-Whitney test. Error bars represent SEM.
Figure S3 (Related to Figure 4) – The effect of RKV supplementation on liver parasite load is not dependent on increased expression of iNOS or of interferon-stimulated genes (ISGs) (A) Expression of iNOS in whole livers of Ctrl and RKV-supplemented mice at 46 hpi. Pool of 3 independent experiments. Unpaired t-test. (B) Expression of five ISGs in RKV-supplemented and Ctrl mice at different timepoints during *P. berghei* liver infection. Pool of 2 – 4 independent experiments. Kruskal-Wallis with post-test Dunn’s. Error bars represent SEM.
Figure S4 (Related to Figure 5)– RKV-dependent parasite elimination is dependent on the immune system but is not singly mediated by either hepatocytes, macrophages, monocytes, neutrophils, NK cells or ILCs. (A) Alb-Cre.MyD88\textsuperscript{ff}, which lack MyD88 specifically on hepatocytes, LysM-Cre.MyD88\textsuperscript{ff}, which lack MyD88 specifically on myeloid cells, and the corresponding littermate control mice (MyD88\textsuperscript{ff}) were allowed to drink Ctrl and RKV supplemented water before infection with Plasmodium sporozoites. Liver load was assessed at 46 hpi. Pool of > 3 and 2 independent experiments, for Alb-Cre.MyD88\textsuperscript{ff} and LysM-Cre.MyD88\textsuperscript{ff}, respectively. (B) The efficiency of the depletion of phagocytes by clodronate administration was assessed at 46 hpi by qRT-PCR, by quantifying the expression of Clec4f (a marker of Kupffer cells), CD68 (a marker of monocytes and macrophages) and F4/80 (a marker of macrophages) in whole livers. Pool of 2 independent experiments. (C) The efficiency of the depletion of monocytes by anti-CCR2 administration was assessed at 46 hpi by flow cytometry. After extraction, liver leukocytes were stained with LIVE/DEAD
Fixable Aqua Dead Cell Staining kit, anti-CD11b, anti-CD11c, anti-Ly6C and anti-Ly6G. Monocytes were defined as Ly6C⁺ Ly6G⁻ cells inside the CD11b⁺ CD11c⁻ population. One experiment. (D) The efficiency of the depletion of neutrophils and monocytes by anti-Gr1 administration was assessed at 46 hpi by flow cytometry. Total liver leukocytes were stained with LIVE/DEAD Fixable Aqua Dead Cell Staining kit, anti-CD11b, anti-CD11c, anti-Ly6C and anti-Ly6G. Neutrophils were defined Ly6G⁺ Ly6C⁻ cells and monocytes as Ly6C⁺ Ly6G⁻ cells, both inside the CD11b⁺ CD11c⁻ population. Representative experiment out of 3 independent experiments. (E) The efficiency of the depletion of NK cells by anti-NK1.1 administration was assessed at 46 hpi by flow cytometry. Liver leukocytes were stained with LIVE/DEAD Fixable Aqua Dead Cell Staining kit, anti-NK1.1 and anti-TCRβ. NK cells were defined as NK1.1⁺ TCRβ⁻ cells inside the total live population. Representative experiment out of 3 independent experiments. (F) The efficiency of the depletion of ILCs by administration of anti-Thy1.2 to Rag2⁻/⁻ mice was assessed at 46 hpi by flow cytometry. Total liver leukocytes were stained with LIVE/DEAD Fixable Aqua Dead Cell Staining kit, anti-CD45, anti-CD3ε, anti-Gr1, anti-CD11b, anti-CD11c, anti-B220, anti-Ter119 and anti-CD127. ILCs were defined as Lineage⁻ CD127⁺ cells inside the live CD45⁺ population. Lineage: anti-CD3ε, anti-Gr1, anti-CD11b, anti-CD11c, anti-B220 and anti-Ter119. One experiment. Error bars represent SEM. (A, C and F) Two-tailed Mann-Whitney test; (B, D and E) Unpaired t-test. ** p < 0.01 and *** p < 0.001.
| Gene | forward primer (5’ - 3’) | reverse primer (5’ - 3’) |
|------|--------------------------|--------------------------|
| Pb18S | AAGCATTAAATATAAGGAATACATCCTTAC | GGAGATGGTTTGACGATTTATGT |
| Hprt | TTTGCTGAACTGCTGATTAC | CAAGACATTCTTTCCAGTAAAGTT |
| Ifit1 | CTTTACAGCAACCTAGGGAGGA | GCAGCTTCCATGTAAGTAGGAC |
| Ifi44 | TCAGATCCATGAAACCAATACAC | CAAATAGCAATGCCCATGTTT |
| Usp18 | CGTGCTTTGAGGTCATTGTTG | GGTGGAGTTCCACAACCTTC |
| Ifit3 | CTGGAATCGTCTAGGCACCAAC | TGGACATACTCCTCCCTCAG |
| Irf7 | TTCAGGACTTTTTCCTCCAGGA | TGTAGTGTTGGAACCTCAG |
| Hamp | CCAATCTCCATTCAACAGATG | AACAGATACCAACTGGGAA |
| Hmox1 | GTCTCCTGAGGAGGCATATC | TGCTGAGTAAACACTCTTG |
| Prdx1 | GTTGCCGCTCCTGTTGGAAGAGAT | ATCACTGCCAGTTTCCAGCCAGC |
| Prdx2 | GTTCTCCGGCTCCATTCACAC | GCCCTCCAGGGCTGAGTG |
| Prdx5 | GCCGGAGGACTGTGTCGG | CTTCCACCGTCAGGGGCAA |
| Prdx6 | CACCACGACAGGAATTGTGATG | TCAGTCCTCTCCCTTTCCAGT |
| Nox2 | TCGAGTGTCTCATCCAAAGC | CTCTTCAGGTTCCAGAGT |
| Nox4 | TCAGGACAGATGCTGATGCT | CTGGAAAACTTCCCTGAGTG |
| Sod1 | TACTGATGGAGTGGAAACC | GAAACATTCCACTCCAG |
| Sod2 | GCTTGATAGCCCTCCAGCAA | ACTGAATTTCAATGGTG |
| Cat | TCAGGAGCGCCCTTTGCTTGT | ACTCGAGCAGGTTAGGGACA |
| Txrdl | ATGGACAGTCCCATCCCCGGA | GCCGCCAGACAGTTCCATAG |
| Txn1 | TGCTACGGTGGCTGAGTTGC | TCGACAGCAACACTCCTG |
| Srmx1 | AGTAGGAGGCTGACACCGG | AGAGCCTGTTGGACAGAT |
| Gsta2 | TGAGAATGGTAGGAAGCCACGG | ATTGGGAGCTGAGTGGGAA |
| Gpx1 | CAAATGGAAAAATGGGCCTCGA | GTTCCCAGTGAATCTTG |
| Gsr | ATCGTGATGGACTTTGAGAT | GGTGGGAGTAGCACAAGC |
| Clec4f | TGAGGGATTTAAGACAGCAGCCT | TCAGATCCCTAAGGCCTCTG |
| Cd68 | AGCTGCGCTGACAGGGACACT | AGGAGGCAAGGGCAAATG |
| F4/80 | CCCAGACCTCCCTACAGAGT | GTGCCAGAGTGAGT |

Table S1 (Related to Figures 1-5)- List of primer sequences used for gene expression quantification.
TRANSPARENT METHODS

Chemicals

RPMI 1640, RPMI 1640 without arginine, William’s E, PBS pH 7.4, trypsin, FBS, non-essential amino acids, penicillin/streptomycin, glutamine, HEPES pH 7, liver perfusion medium (LPM) and liver digestion medium (LDM) were purchased from Gibco/Invitrogen. L-arginine hydrochloride, L-lysine and L-valine were purchased from FisherScientific. All other chemicals were obtained from Sigma, unless otherwise specified.

Cells

Huh7 cells were cultured in RPMI 1640 medium supplemented with 10% v/v FBS, 1% v/v non-essential amino acids, 1% v/v penicillin/streptomycin, 1% v/v Glutamine and 1% v/v HEPES, pH 7 and maintained at 37 °C with 5% CO₂. Mouse primary hepatocytes were cultured in William’s E medium supplemented with 4% v/v FBS and 1% v/v penicillin/streptomycin and maintained at 37 °C with 5% CO₂.

Mice

All animals used in this study were housed in the facilities of Instituto de Medicina Molecular João Lobo Antunes (iMM, Lisbon, Portugal), with a maximum of five animals per cage, and free access to water and food. C57BL/6J wild-type (WT) mice were purchased from Charles River Laboratories (L’Arbresle, France). Nos2-/- mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Ifnar-/-, MyD88-/- and Rag2-/- experimental mice, and Alb-Cre and LysM-Cre breeders were purchased from Instituto Gulbenkian de Ciência (IGC, Lisbon, Portugal). All other mouse strains were obtained from breedings established at iMM’s rodent facility. Four weeks old male mice were used in all experiments that employed exclusively C57BL/6J WT mice. Both male and female 4 to 8 weeks old mice were used in experiments that employed genetically deficient mice. In the latter experiments, 4 to 8 weeks old WT or littermate male and/or female mice were used to match gender and age of the genetically deficient mice. All animal experiments were performed in strict compliance to the
guidelines of iMM’s animal ethics committee (ORBEA) and the Federation of European Laboratory Animal Science Associations (FELASA). In the experiments in which the infection was allowed to proceed to the blood, animals were humanely euthanized at the first behavioral signs of onset of experimental cerebral malaria (ECM).

Parasites

Sporozoites were isolated from the salivary glands of infected female *Anopheles stephensi* mosquitoes bred at iMM’s insectary facility, prior to being employed in infections. A GFP/luciferase-expressing *P. berghei* ANKA parasite line (676m1cl1 line) was used in all experiments (Ploemen et al., 2009), with the exception of the flow cytometry experiments, in which a GFP-expressing *P. berghei* ANKA parasite line (259cl1 line) was employed (Franke-Fayard et al., 2004) and the *P. yoelii* experiment, in which a GFP-expressing *P. yoelii* (strain 17XNL) was employed (Ono et al., 2007).

Isolation of mouse primary hepatocytes

Mouse primary hepatocytes were isolated using a modified two-step perfusion protocol followed by a Percoll purification step, as previously described (Goncalves et al., 2007, Liehl et al., 2014, Meireles et al., 2017). Mice were euthanized by CO$_2$ inhalation and immediately processed for cannulation of the portal vein using a 26-gauge needle, followed by the sectioning of the inferior vena cava (IVC) to allow the fluid to drain. The liver was perfused with liver perfusion medium (LPM), followed by liver digestion medium (LDM). Intermittent clamping of the IVC was performed during LDM perfusion to improve tissue digestion. After digestion, the liver was excised and the cells were liberated, sequentially filtered through a 100 μm and a 70 μm cell strainer and spun at 50×g for 3 min. The pellet was resuspended in William’s Medium E with 10% v/v of FBS, carefully overlaid on a 60% v/v Percoll solution (1:1) and spun at 750×g for 20 min, without break, at 20 °C. Viable hepatocytes deposited in the pellet were washed with William’s E Medium with 10% v/v FBS, spun at 50×g for 3 min and resuspended in complete William’s E Medium (supplemented with 4% v/v FBS and 1% v/v
penicillin/streptomycin). Hepatocytes were then plated at a density of \(1.0 \times 10^5\) in 24-well plates. Viability and yield were assessed by trypan blue staining.

**In vitro and ex vivo amino acid supplementation**

In the conditions with physiological concentrations of Arg, the medium of Huh7 cells or mouse primary hepatocytes was replaced by Arg-free medium supplemented with 100 µM Arg. In the conditions in which there is supplementation of Arg, the approximate supraphysiological concentration of this amino acid which is normally present in RPMI, 1 mM, was added. Supplementations with Lys and Val, were performed by adding 20 mM of each of these amino acids to medium with physiological (K, V and KV) or supraphysiological concentrations of Arg (RK, RV, RKV). These concentrations of Lys and Val were chosen because they have been shown to completely inhibit arginase activity in rat primary hepatocytes at physiological concentrations of Arg (Lerzynski et al., 2006).

**Overall in vitro infection by luminescence**

Overall hepatic infection was determined by measuring the luminescence intensity in Huh7 cells infected with the above referred GFP/luciferase-expressing *P. berghei* line, as previously described (Ploemen et al., 2009). Huh7 cells (\(1.0 \times 10^4\) per well) were seeded in 96-well plates the day before infection. Sporozoite addition was followed by centrifugation at 1800xg for 5 min. Medium was replaced approximately 2 hpi by the appropriate medium. Parasite infection load was measured 48 hpi by a bioluminescence assay (Biotium) using a multiplate reader Infinite M200 (Tecan). Cell viability was assessed by the CellTiter-Blue assay (Promega) according to the manufacturer’s protocol.

**Quantification of *P. berghei* parasite numbers and development by flow cytometry**

Intracellular parasite numbers and development were assessed by determining the percentage of GFP\(^+\) cells and by measuring the intensity of the GFP signal of mouse
primary hepatocytes infected with a GFP-expressing *P. berghei* line at 48 hpi, as previously described (Prudencio et al., 2008). Primary hepatocytes (1.0 × 10^5 per well) were infected with 5.0 × 10^4 sporozoites one day after being plated and the medium was replaced by the appropriate medium 2 h after infection. Cells were collected for flow cytometry analysis at 48 hpi and analyzed on a Becton Dickinson FACSCalibur. Data acquisition and analysis were carried out using the CELLQuest (version 3.1.1 f1, Becton Dickinson) and FlowJo (version 6.4.7, FlowJo) software packages, respectively.

**In vivo amino acid supplementation**

The drinking water of 4 to 8 weeks old mice, was replaced by sterilized water containing 2.5% (w/v) L-arginine hydrochloride (FisherScientific), 2.5% (w/v) L-lysine (FisherScientific), 2.5% (w/v) L-valine (FisherScientific) or a combination of the three amino acids (RKV). The mice were allowed to drink *ad libitum* for 4 weeks, unless otherwise specified. Non-supplemented, sterilized water was provided to Ctrl mice. The supplementation was maintained until completion of the experiment.

**In vivo treatments**

C57BL/6J WT mice were lethally irradiated (900 rad) in an Irradiator Gammancell ELAN 3000, one day before *P. berghei* sporozoite injection. For depletion of phagocytic cells, 200 µL of liposome-encapsulated clodronate (Clodronate Liposomes) were injected i.v. 2 days before infection. Mice injected with 200 µL of liposome-encapsulated PBS were used as controls. Monocytes were depleted by the i.p. injection of 20 µg of anti-CCR2 antibody (clone MC-21; kindly provided by Matthias Mack (Mack et al., 2001)) daily from day -2 to day 1 post-infection. Two hundred and fifty µg of anti-Gr1 (clone RB6-8C5; BioXCell) were injected i.p. 2 h after infection, to deplete both neutrophils and monocytes. For NK cell depletion, 150 µg of anti-NK1.1 antibody (clone PK136; BioXCell) were injected i.p. 1 day prior to infection. Finally, to deplete ILCs, Rag2⁻ mice were injected i.p. with 200 µg of anti-Thy1.2 antibody (clone 30H12;
kindly provided by Marc Veldhoen, iMM), 1 day before infection. Ctrl mice were injected with PBS, or with IgG2a or IgG2b isotype control antibodies (clones 2A3 and LTF-2, respectively; BioXCell).

**In vivo infection and liver collection**

Mice were infected intravenously, through retro-orbital injection of $1.0 \times 10^4$ *P. berghei* sporozoites. Livers were collected at 46 hours post-infection (hpi), unless otherwise specified, and homogenized in 3 mL of denaturing solution (4 M guanidine thiocyanate; 25 mM sodium citrate pH 7, 0.5% w/v N-lauroylsarcosine and 0.7% v/v β mercaptoethanol in DEPC-treated water). In some experiments, one of the liver lobes was fixed in 4% paraformaldehyde (PFA) for immunofluorescence or histopathology analyses. In experiments in which immune cell populations were depleted, a section of the liver was used to extract total liver leukocytes, as described below.

**Bioluminescence analyses of in vivo hepatic infection and blood parasite load**

*In vivo* hepatic parasite load was determined by real-time *in vivo* imaging of the infected mice at 45-47 hpi, using the *in vivo* IVIS Lumina Imaging System, as previously described (Ploemen et al., 2009). Briefly, animals were anesthetized using isoflurane to allow the subcutaneous (s.c.) injection (in the neck) of 200 μL D-luciferin (PerkinElmer) dissolved in PBS (10 mg/ml). After 5 min, animals were anesthetized through intraperitoneal (i.p.) injection of a solution of Ketamine/Xylazine to allow the bioluminescent measurements, which were performed around 10 min after the injection of D-luciferin. Before every experiment, the belly of the animals was shaved to allow for a better detection of the bioluminescent signal.

The presence of luciferase-expressing erythrocytic-stage parasites was monitored daily, from day 2 after infection, as described in (Zuzarte-Luis et al., 2014). Five μL of blood was collected from the tail vein into 45 μL of lysis buffer (Firefly Luciferase Kit, Biotium). Luminescence was determined by adding 50 μL of D-luciferin dissolved in firefly luciferase assay buffer (FLAB) to 30 μL of lysate, according to the manufacturer’s instructions, and immediately measured using
a multiplate reader (Tecan, Switzerland). Values of luciferase activity were expressed as relative luminescence units (RLU).

**RNA extraction, cDNA synthesis and qRT-PCR analysis of hepatic infection**

Total RNA was extracted from liver homogenates using the TripleXtractor Direct RNA kit (Grisp), according to the manufacturers’ instructions. Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the NZY First-Strand cDNA synthesis kit (NZYtech), according to the manufacturer’s instructions. The qRT-PCR reaction was performed in a total volume of 10 μL in a ViiA 7 Real-Time PCR system (Applied Biosystems) using the iTaq™ Universal SYBR® Green kit (BioRad). Parasite load was quantified using primers specific to *P. berghei* 18S RNA (Table S1). The expression of the mouse housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (*Hprt*) was used for normalization in all experiments (Table S1). Analysis of qRT-PCR data was performed using the delta-delta CT relative quantification method.

**Immunohistochemical staining of liver sections**

For microscopy, PFA-fixed liver lobes were cut in 50 μm sections and were incubated in permeabilization/blocking solution (1% w/v BSA, 0.5% v/v Triton-X100 in PBS) at room temperature for 1 h, followed by a 2 h incubation at room temperature with an anti-UIS4 antibody (dilution 1:500). Liver sections were further incubated in a 1:300 dilution of anti-GFP-Alexa488 antibody (Invitrogen) and anti-goat Alexa-Fluor 568 (Invitrogen) in the presence of a 1:1000 dilution of Hoechst 33342 (Invitrogen) and a 1:100 dilution of Phalloidin-660 (Invitrogen) for actin staining for 1 h. After washing, the liver sections were mounted on microscope slides with Fluoromount (SouthernBiotech). Widefield images for size determination were acquired in a Zeiss Axiovert 200M microscope. Images were processed with ImageJ software (version 1.47).

**Histology analyses**
Mice were sacrificed by CO₂ narcosis. Necropsy was performed and liver and kidneys were collected, fixed in 10% neutral buffered formalin and processed for routine histology. Four µm sections were stained with hematoxylin and eosin (HE), and analyzed by a pathologist blinded to experimental groups on a Leica DM2000 microscope coupled to a Leica MC170 camera. Lesions were recorded (diagnosed according to previously published criteria (Thoolen et al., 2010, Frazier et al., 2012)), and inflammation was scored according to a 5-tier severity scale (0, absent; 1, minimal; 2, mild; 3, moderate; 4, marked).

**Plasma biochemistry**

Blood was collected terminally by cardiac puncture and plasma was separated from the cells by centrifugation (4000xg, 10 min, 4˚C). The following parameters were measured in Ctrl and RKV-supplemented mouse plasma (DNAtech, Lisbon, Portugal): Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Total protein, Total bilirrubin, Blood urea nitrogen (BUN), Gamma-glutamyltransferase (GGT), and Creatinine.

**Isolation of liver leukocytes**

Livers were dissociated in a PBS solution containing DNase (2 U per mL), filtered through a 100 µm cell strainer, and centrifuged at 400xg for 5 min. Liver leukocytes were purified by centrifugation using 10 mL of a 35% (v/v) Percoll (Sigma) solution, followed by a centrifugation at 20 °C, 1360xg for 20 min, without break or acceleration. After one wash, RBCs were lysed with 3 mL Ammonium-Chloride-Potassium (ACK) buffer (155 mM Ammonium chloride; 10 mM Potassium bicarbonate; and 0.1 mM Ethylenediaminetetraacetic acid (EDTA) in DEPC-treated water) for 3 min at room temperature (RT). Lysis was stopped by adding PBS with 2% (v/v) foetal bovine serum (FBS, Gibco) and after a final centrifugation at 400xg for 5 min, the cells were resuspended in 200 µL of 2% FBS in PBS for extracellular FACS staining.

**Extracellular FACS staining**
For surface staining, cells were Fc blocked with anti-CD16/CD32 (clone 93; eBioscience) and incubated for 20 minutes on ice with antibodies and LIVE/DEAD Fixable Aqua Dead Cell Staining kit (Molecular Probes) in PBS. The following monoclonal antibodies were used: anti-CD3ε (clone 145-2C11; BD Biosciences), anti-CD11b (clone M1/70; Biolegend), anti-CD11c (clone N418; Biolegend), anti-CD45 (clone 30-F11; Biolegend), anti-Ly6C (clone HK1.4; Biolegend), anti-Ly6G (clone 1A8; Biolegend), anti-NK1.1 (clone PK136; Biolegend), anti-TCRβ (clone H57-597; Biolegend), anti-Gr1 (clone RB6-8C5; eBioscience), anti-B220 (clone RA3-6B2; Biolegend), anti-Ter119 (clone TER-119; Biolegend), and anti-CD127 (clone A7R34; Biolegend). Cells were acquired on a LSR Fortessa X-20 cytometer (BD Biosciences) with the FACSDiva software (version 6.2, BD), and data was analyzed using the FlowJo software.

**Statistical Analyses**

Statistical analyses were performed using the GraphPad Prism 5 software. All datasets were analyzed for normality with the D'Agostino and Pearson omnibus or the Kolmogorov-Smirnov normality tests prior to statistical analyses. Kruskal-Wallis, One-way ANOVA, Two-way ANOVA, Two-tailed Mann-Whitney test, Unpaired t-test, or Log-Rank Mantel-Cox test were used for significance of the differences observed, as indicated in each figure. ns – not significant, * p < 0.05, ** p < 0.01 and *** p < 0.001.